- NervGen Pharma (NGEN) has introduced its Spinal Cord Injury Clinical Advisory Board
- The board will work closely with NervGen as it prepares for its upcoming Phase 1b/2 clinical trial for spinal cord injury
- The compound, NVG-291, has the potential to repair nervous system damage and would represent a completely new treatment paradigm for spinal cord injury patients
- NVG-291, a protein tyrosine phosphatase (PTPσ) modulator, has demonstrated the potential to promote repair mechanisms in the central nervous system
- PTPσ is a protein which has been shown to impede repair following injury to the nervous system
- NervGen Pharma Corp. (NGEN) is down 3.11 per cent, trading at C$2.80 at 12:19 pm ET
NervGen Pharma Corp. (NGEN) has introduced its Spinal Cord Injury (SCI) Clinical Advisory Board.
The board includes five world-class researchers in the field of spinal cord injury: Drs. James Guest, Steven Kirshblum, Brian Kwon, Linda Jones and Daniel Lammertse.
This Clinical Advisory Board will work closely with NervGen as it prepares for its upcoming Phase 1b/2 clinical trial for spinal cord injury with its lead compound, NVG-291.
“We have a tremendous opportunity to provide the first pharmacologic neurorestorative therapy for patients who have suffered a spinal cord injury,” stated Dr. Daniel Mikol, NervGen’s Chief Medical Officer.
Dr. James Guest, Professor of Neurological Surgery at the University of Miami and a member of the scientific faculty at The Miami Project to Cure Paralysis, added, “I have been following the tremendous advances made by Dr. Jerry Silver, the scientific founder of NervGen’s technology, for several years.
NervGen’s President & CEO, Paul Brennan, added, “We are excited and proud to be moving a potentially game-changing therapy into clinical trials next year, not only for SCI, but also for multiple sclerosis and Alzheimer’s disease.
James Guest, MD, Ph.D., FACS, is a Professor of Neurological Surgery at the University of Miami and The Miami Project to Cure Paralysis. Dr. Guest performs experimental translational and clinical research predominantly in SCI, and complex spinal and pain problems.
Steven Kirshblum, MD, is Professor and Chair of the Department of Physical Medicine and Rehabilitation at Rutgers New Jersey Medical School and the Chief Medical Officer for Kessler Institute for Rehabilitation (KIR) and Kessler Foundation (KF).
Brian Kwon, MD, Ph.D., FRCSC, is a Professor in the Department of Orthopaedics at the University of British Columbia, the Canada Research Chair in Spinal Cord Injury, and holds the Dvorak Chair in Spine Trauma.
Linda Jones, PT, Ph.D., serves as a consultant to biotechnology companies, universities, and non-profit organizations to advance spinal cord injury research and is a collaborating faculty member at Thomas Jefferson University.
Daniel Lammertse, MD, is a Clinical Professor of PM&R at the University of Colorado School of Medicine and is an Emeritus Clinical Scientist at Craig Hospital in Englewood Colorado.
NVG-291, a protein tyrosine phosphatase (PTPσ) modulator, has demonstrated the potential to promote repair mechanisms in the central nervous system such as axonal regeneration; remyelination; plasticity; autophagy; and a non-inflammatory phenotype in microglia cells, the innate immune cells of the brain.
PTPσ is a protein that has been shown to impede repair following injury to the nervous system. Nervous system injury can occur because of trauma, such as in the case of spinal cord injury or traumatic brain injury, or as a result of disease-specific mechanisms, such as multiple sclerosis or Alzheimer’s disease.
A Phase 1 trial of NVG-291 in healthy subjects is ongoing. Following completion of the multiple ascending dose portion of the study and ongoing toxicology studies requested by the FDA, NervGen will seek removal of the partial clinical trial hold initiated by the FDA and perform bridging studies in healthy males and in healthy pre-menopausal females.
Following completion of the bridging studies, NervGen intends to initiate a Phase 1b/2a trial in Alzheimer’s disease patients. Concurrently, the company also plans to initiate Phase 1b/2 trials in spinal cord injury and multiple sclerosis with each of these trials planned to start in 2022.
NervGen Pharma Corp. (NGEN) is down 3.11 per cent, trading at C$2.80 at 12:19 pm ET.